NYSE:BMYPharmaceuticals
Bristol Myers Squibb (BMY) Wins FDA Filing And Nvidia Tie Up, Is It Still Undervalued?
Bristol-Myers Squibb (BMY) is back in focus after the FDA accepted its New Drug Application for mezigdomide in relapsed or refractory multiple myeloma, alongside a new AI collaboration with Nvidia for drug discovery.
See our latest analysis for Bristol-Myers Squibb.
The recent FDA filing for mezigdomide and the AI expansion with Nvidia come as Bristol-Myers Squibb’s share price has gained momentum, with a 12.83% 1 month share price return and 13.97% year to date, while the 1 year total...